title: The impact of GGH -401C>T polymorphism on cisplatin-based chemoradiotherapy response and survival in cervical cancer.
abstract: OBJECTIVE
  Cervical cancer is the third most frequent cancer in women worldwide, mostly treated with cisplatin-based chemoradiotherapy. Since it is known that folate metabolism might interfere with cisplatin effectiveness, we intended to study the influence of the Gamma Glutamyl Hydrolase -401C>T polymorphism in treatment response in cervical cancer.
  
  
  METHODS
  We retrospectively reviewed the clinical data of 167 patients with bulky cervical cancer submitted to cisplatin-based chemoradiotherapy. The genotypes of GGH -401C>T SNP were determined by real-time PCR and statistical analysis was performed by χ(2) test and survival analysis.
  
  
  RESULTS
  The genotypes of GGH-401C>T were significantly associated with the response to platinum-based chemoradiotherapy. Treatment response was higher in patients carrying the CC genotype, who presented a significant increased chance of treatment response (survival time in months/genotype: 91 for CC Vs 72 for CT/TT; p=0.035, log rank test). A Cox regression analysis accordingly showed that the presence of the T allele was significantly linked to a worse treatment response (HR=3.036; CI 95% 1.032-8.934, p=0.044).
  
  
  CONCLUSIONS
  The results of our study suggested the potential interest of GGH -401C>T as a predictive factor of the outcome of cervical carcinoma treated with cisplatin-based chemoradiotherapy.
authors.affiliation: Molecular Oncology Unit, Portuguese Institute of Oncology, Porto, Portugal.
authors.forename: Inês Hilário
authors.initials: IH
authors.lastname: Silva
authors.forename: Cristina
authors.initials: C
authors.lastname: Nogueira-Silva
authors.forename: Tiago
authors.initials: T
authors.lastname: Figueiredo
authors.forename: Liliana
authors.initials: L
authors.lastname: Lombo
authors.forename: Ilda
authors.initials: I
authors.lastname: Faustino
authors.forename: Raquel
authors.initials: R
authors.lastname: Catarino
authors.forename: Augusto
authors.initials: A
authors.lastname: Nogueira
authors.forename: Deolinda
authors.initials: D
authors.lastname: Pereira
authors.forename: Rui
authors.initials: R
authors.lastname: Medeiros
mesh_terms: D000328:Adult; D059248:Chemoradiotherapy / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000401:mortality* / Q000628:therapy*; D011623:gamma-Glutamyl Hydrolase / Q000235:genetics* / Q000378:metabolism
chemical_list: D011838:Radiation-Sensitizing Agents; D011623:gamma-Glutamyl Hydrolase; D002945:Cisplatin